Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading pharmaceutical company in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a Phase II clinical study for its small molecule GLP-1 receptor agonist, HRS-7535, for weight loss treatment. This development marks a significant step forward in the company’s efforts to address obesity, a growing global health concern.
HRS-7535 has successfully completed a Phase I study in healthy volunteers, showing promising results regarding safety, tolerability, and favorable pharmacokinetic properties. With the completion of patient enrollment for the Phase II clinical study focused on adult type 2 diabetes (T2DM) patients, Hengrui Medicine is poised to further evaluate the therapeutic potential of HRS-7535. Notably, there is currently no similar product approved globally, indicating the novelty and potential impact of this drug candidate in the market.- Flcube.com
